{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T07:12:40Z","timestamp":1781248360087,"version":"3.54.1"},"reference-count":102,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T00:00:00Z","timestamp":1600646400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005565","name":"Janssen Biotech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014088","name":"AstraZeneca France","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014088","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008021","name":"Bristol-Myers Squibb Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.clml.2020.08.022","type":"journal-article","created":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T23:34:47Z","timestamp":1600385687000},"page":"8-20.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Can Next-Generation PI3K Inhibitors Unlock the Full Potential of the Class in Patients With B-Cell Lymphoma?"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2143-9672","authenticated-orcid":false,"given":"Tycel J.","family":"Phillips","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3482-3331","authenticated-orcid":false,"given":"Jean-Marie","family":"Michot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Ribrag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2020.08.022_bib1","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0140-6736(16)32407-2","article-title":"Non-Hodgkin lymphoma","volume":"390","author":"Armitage","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2020.08.022_bib2","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1182\/blood-2018-08-822148","article-title":"How I treat early relapsing follicular lymphoma","volume":"133","author":"Casulo","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.08.022_bib3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/bjh.14136","article-title":"Guidelines for the management of diffuse large B-cell lymphoma","volume":"174","author":"Chaganti","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.08.022_bib4","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1080\/10428194.2017.1403602","article-title":"Treatment for patients with relapsed\/refractory mantle cell lymphoma: European-based recommendations","volume":"59","author":"Dreyling","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.08.022_bib5","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2016-10-747345","article-title":"Targeting Bruton tyrosine kinase with ibrutinib in relapsed\/refractory marginal zone lymphoma","volume":"129","author":"Noy","year":"2017","journal-title":"Blood"},{"issue":"suppl 5","key":"10.1016\/j.clml.2020.08.022_bib6","doi-asserted-by":"crossref","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","article-title":"Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Tilly","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2020.08.022_bib8","doi-asserted-by":"crossref","first-page":"iv62","DOI":"10.1093\/annonc\/mdx223","article-title":"Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2020.08.022_bib9","doi-asserted-by":"crossref","first-page":"v83","DOI":"10.1093\/annonc\/mdw400","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Dreyling","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2020.08.022_bib10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrc3860","article-title":"PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting","volume":"15","author":"Thorpe","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clml.2020.08.022_bib11","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.clml.2014.01.007","article-title":"Status of PI3K\/Akt\/mTOR pathway inhibitors in lymphoma","volume":"14","author":"Westin","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2020.08.022_bib12","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1080\/14737140.2017.1285702","article-title":"Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow","volume":"17","author":"Greenwell","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.clml.2020.08.022_bib13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3389\/fonc.2013.00040","article-title":"p110\u03b4 PI3 kinase pathway: emerging roles in cancer","volume":"3","author":"Tzenaki","year":"2013","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2020.08.022_bib14","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1080\/13543784.2017.1384815","article-title":"PI3K\u03b4-selective and PI3K\u03b1\/\u03b4-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma","volume":"26","author":"Lampson","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.clml.2020.08.022_bib15","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1200\/JCO.19.00215","article-title":"Targeting PI3K-gamma in non-Hodgkin lymphoma","volume":"37","author":"Fruman","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.08.022_bib16","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1093\/annonc\/mdx392","article-title":"Revival of PI3K inhibitors in non-Hodgkin\u2019s lymphoma","volume":"28","author":"Batlevi","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2020.08.022_bib17","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1053\/j.seminoncol.2016.11.011","article-title":"PI3K signaling pathway in normal B cells and indolent B-cell malignancies","volume":"43","author":"Pongas","year":"2016","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clml.2020.08.022_bib18","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.2147\/DDDT.S142406","article-title":"Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib","volume":"12","author":"Krause","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.clml.2020.08.022_bib19","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1365-2141.2005.05784.x","article-title":"Assessment of somatic mutations in phosphatidylinositol 3-kinase gene in human lymphoma and acute leukaemia","volume":"131","author":"Bousquet","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.08.022_bib20","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3324\/haematol.2013.087171","article-title":"Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies","volume":"99","author":"Jabbour","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2020.08.022_bib21","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1038\/sj.leu.2404873","article-title":"PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma","volume":"21","author":"Abubaker","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2020.08.022_bib22","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1182\/blood-2006-04-015586","article-title":"Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma","volume":"108","author":"Rudelius","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.08.022_bib23","doi-asserted-by":"crossref","first-page":"5142","DOI":"10.1182\/blood-2007-07-103481","article-title":"Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma","volume":"111","author":"Dal Col","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.08.022_bib24","doi-asserted-by":"crossref","first-page":"5724","DOI":"10.1158\/1078-0432.CCR-08-3215","article-title":"Phosphatidylinositol 3\u2032-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma","volume":"15","author":"Psyrri","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2020.08.022_bib25","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1479-5876-12-10","article-title":"Frequent copy number variations of PI3K\/AKT pathway and aberrant protein expressions of PI3K subunits are associated with inferior survival in diffuse large B cell lymphoma","volume":"12","author":"Cui","year":"2014","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.clml.2020.08.022_bib26","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.08.022_bib27","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1093\/annonc\/mdx289","article-title":"Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2020.08.022_bib28","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","article-title":"Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma","volume":"35","author":"Dreyling","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.08.022_bib29","article-title":"Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study [e-pub ahead of print]","author":"Dreyling","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2020.08.022_bib30","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.18.00915","article-title":"DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma","volume":"37","author":"Flinn","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.08.022_bib31","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.3324\/haematol.2016.151738","article-title":"Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent\u2013refractory follicular lymphoma: a subgroup analysis of a phase 2 study","volume":"102","author":"Salles","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2020.08.022_bib32","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S1470-2045(18)30082-2","article-title":"Umbralisib, a novel PI3K\u03b4 and casein kinase-1\u03b5 inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study","volume":"19","author":"Burris","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2020.08.022_bib33","author":"Fowler","year":"2019"},{"key":"10.1016\/j.clml.2020.08.022_bib34","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1182\/blood-2018-08-867499","article-title":"Parsaclisib, a potent and highly selective PI3K\u03b4 inhibitor, in patients with relapsed or refractory B-cell malignancies","volume":"133","author":"Forero-Torres","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.08.022_bib35","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1182\/blood-2017-10-812701","article-title":"Phase 1 study of the PI3K\u03b4 inhibitor INCB040093 \u00b1 JAK1 inhibitor itacitinib in relapsed\/refractory B-cell lymphoma","volume":"132","author":"Phillips","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.08.022_bib36","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41408-018-0055-x","article-title":"Final results of a phase 1b study of the safety and efficacy of the PI3K\u03b4 inhibitor acalisib (GS-9820) in relapsed\/refractory lymphoid malignancies","volume":"8","author":"Kater","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2020.08.022_bib37","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.1182\/blood-2019-126707","article-title":"Preliminary results from a phase I study of SHC014748M in patients with relapsed or refractory indolent B-cell lymphomas","volume":"134","author":"Xu","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.08.022_bib38","doi-asserted-by":"crossref","first-page":"7519","DOI":"10.1200\/JCO.2018.36.15_suppl.7519","article-title":"Initial results of a dose escalation study of a selective and structurally differentiated PI3K\u03b4 inhibitor, ME-401, in relapsed\/refractory (R\/R) follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL)","volume":"36","author":"Soumerai","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.08.022_bib39","first-page":"EP1174","article-title":"The PI3K\u03b4 inhibitor ME-401 is well-tolerated on intermittent schedule and produces a high-rate of durable responses in relapsed\/refractory (R\/R) indolent B-cell malignancies","author":"Pagel","year":"2020","journal-title":"EHA"},{"key":"10.1016\/j.clml.2020.08.022_bib40","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.clml.2019.10.013","article-title":"A\u00a0First-in-human study of tenalisib (RP6530), a dual PI3K delta\/gamma inhibitor, in patients with relapsed\/refractory hematologic malignancies: results from the European Study","volume":"20","author":"Carlo-Stella","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2020.08.022_bib41","doi-asserted-by":"crossref","first-page":"8058","DOI":"10.1200\/JCO.2020.38.15_suppl.8058","article-title":"Safety and efficacy of TQ-B3525, a novel and selective oral PI3K \u03b1\/\u03b4 inhibitor, in Chinese patients with advanced malignancies: a phase I dose-escalation and expansion trial","volume":"38","author":"Wang","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.08.022_bib42","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2019-130401","article-title":"Results of a first in human, dose ascending, phase I study examining the safety and tolerability of KA2237, an oral PI3K p110\u03b2\/\u03b4 inhibitor in patients with relapsed\/refractory (R\/R) B-cell lymphoma","volume":"134","author":"Nastoupil","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.08.022_bib43","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.3324\/haematol.2017.169656","article-title":"Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"102","author":"Younes","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2020.08.022_bib44","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1158\/1078-0432.CCR-14-3262","article-title":"Phase I trial of the pan-PI3K inhibitor pilaralisib (SAR245408\/XL147) in patients with chronic lymphocytic leukemia (CLL) or relapsed\/refractory lymphoma","volume":"21","author":"Brown","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2020.08.022_bib45","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-020-0743-y","article-title":"Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma","author":"Lenz","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2020.08.022_bib46","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.1016\/S2352-3026(18)30030-9","article-title":"Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial","volume":"5","author":"Brown","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2020.08.022_bib47","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/hon.2540","article-title":"Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: a multidisciplinary position paper","volume":"37","author":"Cuneo","year":"2019","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2020.08.022_bib48","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.3109\/10428194.2015.1022770","article-title":"Management of adverse events associated with idelalisib treatment: expert panel opinion","volume":"56","author":"Coutr\u00e9","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.08.022_bib49","series-title":"Aliqopa\u2122 (copanlisib) for Injection, for Intravenous use (Prescribing Information)","year":"2017"},{"key":"10.1016\/j.clml.2020.08.022_bib50","series-title":"Copiktra (duvelisib), Capsules for Oral Use (Prescribing Information)","year":"2018"},{"key":"10.1016\/j.clml.2020.08.022_bib51","series-title":"Zydelig\u00ae (idelalisib) Tablets, for Oral Use (Prescribing Information)","year":"2014"},{"key":"10.1016\/j.clml.2020.08.022_bib52","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00280-015-2891-8","article-title":"Population pharmacokinetic modeling of idelalisib, a novel PI3K\u03b4 inhibitor, in healthy subjects and patients with hematologic malignancies","volume":"77","author":"Jin","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clml.2020.08.022_bib53","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1586\/17474086.2015.1071663","article-title":"Idelalisib for relapsed\/refractory indolent B-cell non-Hodgkin\u2019s lymphoma: an overview of pharmacokinetics and clinical trial outcomes","volume":"8","author":"Davies","year":"2015","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.clml.2020.08.022_bib54","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/annonc\/mdw282","article-title":"First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin\u2019s lymphomas","volume":"27","author":"Patnaik","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2020.08.022_bib55","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/blood-2017-05-786566","article-title":"Duvelisib, a novel oral dual inhibitor of PI3K-delta,gamma, is clinically active in advanced hematologic malignancies","volume":"131","author":"Flinn","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.08.022_bib56","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2013-11-537555","article-title":"A\u00a0phase 1 study of the PI3Kdelta inhibitor idelalisib in patients with relapsed\/refractory mantle cell lymphoma (MCL)","volume":"123","author":"Kahl","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.08.022_bib57","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1182\/blood-2018-99-115670","article-title":"Preliminary safety and efficacy results with an intermittent schedule of the PI3K\u03b4 inhibitor ME-401 alone or in combination with rituximab for B-cell malignancies","volume":"132","author":"Zelenetz","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.08.022_bib58","first-page":"EP1171","article-title":"Feasibility of combining the phosphatidylinositol 3-kinase (PI3K) inhibitor copanlisib with rituximab (R)-based immunochemotherapy in patients (pts) with relapsed indolent non-Hodgkin lymphoma (INHL)","author":"Zinzani","year":"2020","journal-title":"EHA"},{"key":"10.1016\/j.clml.2020.08.022_bib59","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1002\/ajh.25634","article-title":"Combination trial of duvelisib (IPI-145) with rituximab or bendamustine\/rituximab in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia","volume":"94","author":"Flinn","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2020.08.022_bib60","first-page":"EP689","article-title":"Long term results of a phase I\/Ib study of ibrutinib in combination with umbralisib in patients with relapsed\/refractory CLL or MCL","author":"Davids","year":"2020","journal-title":"EHA"},{"key":"10.1016\/j.clml.2020.08.022_bib61","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/S2352-3026(18)30196-0","article-title":"Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study","volume":"6","author":"Davids","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2020.08.022_bib62","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1182\/blood.2019002118","article-title":"Ublituximab and umbralisib in relapsed\/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"134","author":"Lunning","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.08.022_bib63","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1016\/S2352-3026(18)30216-3","article-title":"Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial","volume":"6","author":"Nastoupil","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2020.08.022_bib64","first-page":"EP705","article-title":"Safety and activity of the once daily selective bruton tyrosine kinase (BTK) inhibitor TG-1701 in patients with chronic lymphocytic leukemia (CLL) and lymphoma","author":"Cheah","year":"2020","journal-title":"EHA"},{"key":"10.1016\/j.clml.2020.08.022_bib65","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/bjh.14181","article-title":"Phase Ib trial of the PI3K\/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies","volume":"175","author":"Awan","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.08.022_bib66","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1158\/2159-8290.CD-16-0716","article-title":"Targeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis, and immunotherapy","volume":"6","author":"Okkenhaug","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clml.2020.08.022_bib67","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1124\/jpet.117.244947","article-title":"INCB040093 is a novel PI3K\u03b4 inhibitor for the treatment of B cell lymphoid malignancies","volume":"364","author":"Shin","year":"2018","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.clml.2020.08.022_bib68","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1158\/1535-7163.MCT-13-0709","article-title":"Characterization of the activity of the PI3K\/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway","volume":"13","author":"Yu","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clml.2020.08.022_bib69","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1182\/blood-2016-03-707133","article-title":"Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity","volume":"128","author":"Lampson","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.08.022_bib70","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1124\/jpet.120.265538","article-title":"Parsaclisib is a next-generation PI3Kdelta inhibitor with reduced hepatotoxicity and potent antitumor and immunomodulatory activities in models of B-Cell malignancy","volume":"374","author":"Shin","year":"2020","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.clml.2020.08.022_bib71","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.cell.2006.03.035","article-title":"A\u00a0pharmacological map of the PI3-K family defines a role for p110\u03b1 in insulin signaling","volume":"125","author":"Knight","year":"2006","journal-title":"Cell"},{"issue":"suppl 2","key":"10.1016\/j.clml.2020.08.022_bib72","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.cmi.2018.02.009","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (intracellular signaling pathways: tyrosine kinase and mTOR inhibitors)","volume":"24","author":"Reinwald","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.clml.2020.08.022_bib73","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/hon.133_2629","article-title":"The PI3K\u03b4 inhibitor ME-401 \u00b1 rituximab in relapsed\/refractory (r\/r) follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), and small lymphocytic lymphoma (SLL)","volume":"37","author":"Zelenetz","year":"2019","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2020.08.022_bib74","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.4049\/jimmunol.1700323","article-title":"The PI3K\u03b4-selective inhibitor idelalisib minimally interferes with immune effector function mediated by rituximab or obinutuzumab and significantly augments B cell depletion in\u00a0vivo","volume":"200","author":"Palazzo","year":"2018","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.clml.2020.08.022_bib75","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1158\/1078-0432.CCR-17-2218","article-title":"Synergistic targeting of the regulatory and catalytic subunits of PI3K\u03b4 in mature B-cell malignancies","volume":"24","author":"Cooney","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2020.08.022_bib76","first-page":"401","article-title":"Synergistic suppression of the PI3K inhibitor CAL-101 with bortezomib on mantle cell lymphoma growth","volume":"12","author":"Qu","year":"2015","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.clml.2020.08.022_bib77","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1158\/1535-7163.MCT-16-0840","article-title":"EZH2 inhibition by tazemetostat results in altered dependency on B-cell activation signaling in DLBCL","volume":"16","author":"Brach","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clml.2020.08.022_bib78","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/bjh.15727","article-title":"In\u00a0vitro demonstration of synergism with pixantrone combined with targeted agents in lymphomas","volume":"186","author":"Tarantelli","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.08.022_bib79","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ccell.2016.12.003","article-title":"Simultaneous inhibition of PI3K\u03b4 and PI3K\u03b1 induces ABC-DLBCL regression by blocking BCR-dependent and -independent activation of NF-\u03baB and AKT","volume":"31","author":"Paul","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2020.08.022_bib80","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1182\/blood-2018-08-872465","article-title":"Targeted inhibition of PI3K\u03b1\/\u03b4 is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL","volume":"133","author":"Bojarczuk","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.08.022_bib81","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1182\/bloodadvances.2019000844","article-title":"Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models","volume":"4","author":"Tarantelli","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2020.08.022_bib82","doi-asserted-by":"crossref","first-page":"e0200725","DOI":"10.1371\/journal.pone.0200725","article-title":"The phosphoinositide-3 kinase (PI3K)-\u03b4,\u03b3 inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies","volume":"13","author":"Faia","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2020.08.022_bib83","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1182\/blood-2016-08-731240","article-title":"Silencing c-Myc translation as a therapeutic strategy through targeting PI3K\u03b4 and CK1\u03b5 in hematological malignancies","volume":"129","author":"Deng","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.08.022_bib84","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/bjh.16118","article-title":"Single and combined BTK and PI3K\u03b4 inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomas","volume":"187","author":"Spriano","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.08.022_bib85","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/bjh.15079","article-title":"Venetoclax as a single agent and in combination with PI3K-MTOR1\/2 kinase inhibitors against ibrutinib sensitive and resistant mantle cell lymphoma","volume":"184","author":"Jiang","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.08.022_bib86","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13046-016-0327-x","article-title":"Low dose of lenalidmide and PI3K\/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma","volume":"35","author":"Jin","year":"2016","journal-title":"J\u00a0Exp Clin Cancer Res"},{"key":"10.1016\/j.clml.2020.08.022_bib87","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13045-016-0303-0","article-title":"Synergistic effect of oridonin and a PI3K\/mTOR inhibitor on the non-germinal center B cell\u2013like subtype of diffuse large B cell lymphoma","volume":"9","author":"Qing","year":"2016","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.clml.2020.08.022_bib88","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1182\/blood-2015-03-633156","article-title":"Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed\/refractory indolent lymphoma","volume":"125","author":"Cheah","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.08.022_bib89","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1182\/blood-2015-12-683516","article-title":"Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL","volume":"127","author":"Barr","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.08.022_bib90","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/bloodadvances.2016000976","article-title":"Combinations of idelalisib with rituximab and\/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma","volume":"1","author":"de Vos","year":"2016","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2020.08.022_bib91","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejca.2017.01.024","article-title":"Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer","volume":"76","author":"Massard","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2020.08.022_bib92","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s11523-017-0482-9","article-title":"A\u00a0phase Ib study of the dual PI3K\/mTOR inhibitor dactolisib (BEZ235) combined with everolimus in patients with advanced solid malignancies","volume":"12","author":"Wise-Draper","year":"2017","journal-title":"Target Oncol"},{"key":"10.1016\/j.clml.2020.08.022_bib93","doi-asserted-by":"crossref","first-page":"e1593","DOI":"10.1038\/cddis.2014.525","article-title":"MCL-1 and BCL-xL\u2013dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K\/AKT\/mTOR activation in lymphoid malignancies","volume":"6","author":"Choudhary","year":"2015","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.clml.2020.08.022_bib94","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1080\/13543784.2018.1482273","article-title":"Targeting the B cell receptor pathway in non-Hodgkin lymphoma","volume":"27","author":"Valla","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.clml.2020.08.022_bib95","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.3747\/co.26.4345","article-title":"Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma","volume":"26","author":"Owen","year":"2019","journal-title":"Curr Oncol"},{"key":"10.1016\/j.clml.2020.08.022_bib96","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.2147\/OTT.S102573","article-title":"Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential","volume":"9","author":"Barrientos","year":"2016","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.clml.2020.08.022_bib97","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(18)30145-1","article-title":"Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study","volume":"19","author":"Italiano","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2020.08.022_bib98","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1182\/blood-2015-02-628669","article-title":"CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL","volume":"126","author":"Hagner","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.08.022_bib99","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1158\/1078-0432.CCR-18-1203","article-title":"A\u00a0first-in-human study of novel cereblon modulator avadomide (CC-122) in advanced malignancies","volume":"25","author":"Rasco","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2020.08.022_bib100","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1586\/17474086.2015.1071663","article-title":"Idelalisib for relapsed\/refractory indolent B-cell non-Hodgkin\u2019s lymphoma: an overview of pharmacokinetics and clinical trial outcomes","volume":"8","author":"Davies","year":"2015","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.clml.2020.08.022_bib101","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00280-015-2891-8","article-title":"Population pharmacokinetic modeling of idelalisib, a novel PI3K\u03b4 inhibitor, in healthy subjects and patients with hematologic malignancies","volume":"77","author":"Jin","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clml.2020.08.022_bib102","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/annonc\/mdw282","article-title":"First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan\u2013class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin\u2019s lymphomas","volume":"27","author":"Patnaik","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2020.08.022_bib103","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/blood-2017-05-786566","article-title":"Duvelisib, a novel oral dual inhibitor of PI3K-delta,gamma, is clinically active in advanced hematologic malignancies","volume":"131","author":"Flinn","year":"2018","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020305097?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020305097?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:35:07Z","timestamp":1761870907000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265020305097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":102,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S2152265020305097"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2020.08.022","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can Next-Generation PI3K Inhibitors Unlock the Full Potential of the Class in Patients With B-Cell Lymphoma?","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2020.08.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}